Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Gerlinger

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Cancer Research Communications|November 22, 2023
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγAlice Newey, Lu Yu, Louise J Barber, et al.
Trends in Cancer|March 8, 2016
Cancer Evolution and the Limits of Predictability in Precision Cancer MedicineKamil A Lipinski, Louise J Barber, Matthew N Davies, et al.
Haematologica|January 29, 2010
Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on managementMarco Gerlinger, Ama Z S Rohatiner, Janet Matthews, et al.
European Urology|May 20, 2014
Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implicationsMarco Gerlinger, James W Catto, Torben F Orntoft, et al.
Medical Oncology (Northwood, London, England)|July 5, 2022
Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomesJason A Somarelli, James DeGregori, Marco Gerlinger, et al.
Future Oncology (London, England)|July 23, 2024
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancerAnwaar Saeed, Josep Tabernero, Aparna Parikh, et al.
British Journal of Cancer|April 18, 2026
PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisationLucy Flanders, Thomas Savy, Miriam Ficial, et al.
Clinical Colorectal Cancer|November 9, 2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceKhurum Khan, Jayant K Rane, David Cunningham, et al.
The Journal of Pathology|May 30, 2013
Parallel evolution of tumour subclones mimics diversity between tumoursPierre Martinez, Nicolai Juul Birkbak, Marco Gerlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Prognostic and predictive markers in metastatic renal cell carcinomaMuhammad A Khattak, Farrah Bakr, Marcin Krzystanek, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Cancer Research Communications|November 22, 2023
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγAlice Newey, Lu Yu, Louise J Barber, et al.
Trends in Cancer|March 8, 2016
Cancer Evolution and the Limits of Predictability in Precision Cancer MedicineKamil A Lipinski, Louise J Barber, Matthew N Davies, et al.
Haematologica|January 29, 2010
Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on managementMarco Gerlinger, Ama Z S Rohatiner, Janet Matthews, et al.
European Urology|May 20, 2014
Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implicationsMarco Gerlinger, James W Catto, Torben F Orntoft, et al.
Medical Oncology (Northwood, London, England)|July 5, 2022
Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomesJason A Somarelli, James DeGregori, Marco Gerlinger, et al.
Future Oncology (London, England)|July 23, 2024
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancerAnwaar Saeed, Josep Tabernero, Aparna Parikh, et al.
British Journal of Cancer|April 18, 2026
PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisationLucy Flanders, Thomas Savy, Miriam Ficial, et al.
Clinical Colorectal Cancer|November 9, 2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceKhurum Khan, Jayant K Rane, David Cunningham, et al.
The Journal of Pathology|May 30, 2013
Parallel evolution of tumour subclones mimics diversity between tumoursPierre Martinez, Nicolai Juul Birkbak, Marco Gerlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Prognostic and predictive markers in metastatic renal cell carcinomaMuhammad A Khattak, Farrah Bakr, Marcin Krzystanek, et al.
Pageof 7